- Home
- WTM vs LEGN Comparison
WTM vs LEGN Comparison
Compare WTM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTM | LEGN |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WTM | LEGN |
|---|---|---|
| Price | $2,144.08 | $29.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.33 |
| AVG Volume (30 Days) | 15.7K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.05% | N/A |
| EPS Growth | ★ 379.05 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,735,000,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.76 | N/A |
| 52 Week Low | $1,648.00 | $16.24 |
| 52 Week High | $2,333.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | WTM | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 65.66 |
| Support Level | $2,025.76 | $25.01 |
| Resistance Level | $2,236.29 | $29.69 |
| Average True Range (ATR) | 53.43 | 2.17 |
| MACD | 2.84 | -0.12 |
| Stochastic Oscillator | 65.92 | 82.32 |
Price Performance
Historical ComparisonAbout WTM White Mountains Insurance Group Ltd.
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations. The company has four reportable segments: Ark/WM Outrigger, HG Global, Kudu and Distinguished.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.